Cure My Disease

Don't miss your cure!

 Log in / Sign up

New needle combo zaps returning liver tumors after failed chemo

NCT ID NCT07192172

Completed Disease control Sponsor: Seoul National University Hospital Source: ClinicalTrials.gov ↗

First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This study tested a special type of radiofrequency ablation using two cooled needles that also release saline to treat liver cancer that came back after chemoembolization. The goal was to see if this technique could better destroy the tumor and prevent it from growing back. One hundred adults with recurrent liver cancer were treated, and researchers tracked how many had tumor regrowth at the treatment site over two years.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance
Twin Internally Cooled-Perfusion (TICP) electrodes for bipolar radiofrequency ablation
What this could lead to
If successful, this technique could offer a more effective way to destroy recurrent liver tumors after initial treatment, potentially improving local control and survival.
What could go wrong
This is a single-center, non-randomized study with only 100 participants. The results may not apply to all patients, and the procedure carries risks like bleeding or damage to nearby structures.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for ABLATION TECHNIQUES, RFA are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

hepatocellular carcinoma liver and intrahepatic bile duct neoplasm Liver Neoplasms

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

ABLATION TECHNIQUES, RFA HEPATOCELLULAR CARCINOMA LIVER NEOPLASMS RECURRENT HCC

Contacts and locations

Locations

  • Seoul National University Hosptial

    Seoul, Seoul, 03080, South Korea

More trials for these conditions

Other studies related to the condition(s) this trial covers.